ReviewOncogene2003
Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
Review in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15.Leukemia · 2022Article
- The tumour immune microenvironment in oesophageal cancer.British journal of cancer · 2021Review
- Review
- Characterising the prognostic potential of HLA-DR during colorectal cancer development.Cancer immunology, immunotherapy : CII · 2020Article
- Expressions of HLA Class II Genes in Cutaneous Melanoma Were Associated with Clinical Outcome: Bioinformatics Approaches and Systematic Analysis of Public Microarray and RNA-Seq Datasets.Diagnostics (Basel, Switzerland) · 2019Article
- Article
- HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.Cancer immunology, immunotherapy : CII · 2017Article
- The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.Cancer medicine · 2017Article
- Distinct MHC gene expression patterns during progression of melanoma.Genes, chromosomes & cancer · 2010Article
- The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells.Immunology · 2009Article
- HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.Cancer immunology, immunotherapy : CII · 2009Review
- Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry.Molecular & cellular proteomics : MCP · 2009Article
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.Oncogene · 2008Review
- Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets.BMC cancer · 2008Article
- An alternative flow cytometry strategy for peripheral blood dendritic cell enumeration in the setting of repetitive GM-CSF dosing.Journal of translational medicine · 2006Article
- Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.Cancer immunology, immunotherapy : CII · 2005Review
- CIITA methylation and decreased levels of HLA-DR in tumour progression.British journal of cancer · 2004Article
- HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.OncoimmunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracellular signals, delivered in professional antigen-presenting cells following the engagement of major histocompatibility complex (MHC) class II molecules, activate a variety of cellular functions that also contribute to efficient antigen presentation. As far as human malignancies, the signaling ability of human leukocyte antigens (HLA) class II molecules is a rather well-characterized event in hematologic tumors; in contrast, very limited evidences are available in solid neoplasias of different histotypes that may constitutively express HLA class II antigens. Among solid malignancies, a significant proportion of human cutaneous melanomas have been shown to express HLA class II molecules, and cutaneous melanoma undoubtedly represents a 'model disease' to investigate tumor immunobiology, to unveil the molecular basis underlying the interactions between neoplastic cells and host's immune system, and ultimately to set up new bio-immunotherapeutic approaches. Upcoming preclinical evidences unveil a signaling potential of HLA-DR antigens expressed on melanoma cells, and suggest for the clinical implication of HLA class II molecules as novel therapeutic targets. Therefore, in this review, we will focus on the emerging role of HLA class II antigens as intracellular signal transducing elements in neoplastic cells of the melanocytic lineage, emphasizing their foreseeable role in targeted therapy of human melanoma and potentially of HLA class II antigens-positive tumors of different histology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.